INBS vs OPRX vs QDEL vs CUE vs SEER

For growth investors, Cue Biopharma, Inc.

(CUE) is the stronger pick with 195. 7% revenue growth year-over-year, versus -8. 1% for Seer, Inc. (SEER). OptimizeRx Corporation (OPRX) offers the better valuation at 24. 6x trailing P/E (7. 0x forward), making it the more compelling value choice. Analysts rate OptimizeRx Corporation (OPRX) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, QuidelOrtho Corporation is actually cheaper at 6.

4x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, OptimizeRx Corporation (OPRX) delivered a total return of -87.

3%, compared to -99. 8% for Intelligent Bio Solutions Inc. (INBS). Over 10 years, the gap is even starker: OPRX returned +110. 5% versus INBS's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Seer, Inc.

(SEER) is the lower-risk stock at 0. 84β versus QuidelOrtho Corporation's 2. 59β — meaning QDEL is approximately 208% more volatile than SEER relative to the S&P 500. On balance sheet safety, OptimizeRx Corporation (OPRX) carries a lower debt/equity ratio of 4% versus 146% for QuidelOrtho Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Cue Biopharma, Inc.

(CUE) is pulling ahead at 195. 7% versus -8. 1% for Seer, Inc. (SEER). On earnings-per-share growth, the picture is similar: OptimizeRx Corporation grew EPS 124. 5% year-over-year, compared to -3. 0% for Seer, Inc.. Over a 3-year CAGR, CUE leads at 180. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

OptimizeRx Corporation (OPRX) is the more profitable company, earning 4.

7% net margin versus -620. 9% for Seer, Inc. — meaning it keeps 4. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OPRX leads at 10. 7% versus -717. 7% for SEER. At the gross margin level — before operating expenses — CUE leads at 87. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, QuidelOrtho Corporation (QDEL) trades at 6.

4x forward P/E versus 7. 0x for OptimizeRx Corporation — 0. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OPRX: 156. 4% to $17. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Seer, Inc.

(SEER) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 84)). Cue Biopharma, Inc. (CUE) carries a higher beta of 2. 34 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SEER: -96. 7%, CUE: -89. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: INBS is a small-cap quality compounder stock; OPRX is a small-cap high-growth stock; QDEL is a small-cap quality compounder stock; CUE is a small-cap high-growth stock; SEER is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.